Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- All Municipalities to Get 2nd Doses for HCPs by Week of May 10: Minister
March 15, 2021
- No Significant Concerns Observed with Pfizer COVID-19 Vaccine: Japan Safety Panels
March 15, 2021
- Site Pain Common with COVID-19 Vaccine, but It Improves in 3 Days: Safety Follow-Up
March 15, 2021
- MHLW Don’t Rule Out 7 Doses per Vial, but Won’t Recommend It for Pfizer Vaccine: Minister
March 15, 2021
- MHLW Panel Determines Medical Need for 4 Drugs Including Acetaminophen
March 15, 2021
- Olumiant, 7 More APIs Earn Orphan Designation: MHLW
March 12, 2021
- 2nd-Dose Shot Starts for COVID-19 Vaccination in Japan
March 12, 2021
- AMED to Fund 22 More Projects to Develop COVID-19 Treatments
March 11, 2021
- Govt Won’t Widely Recommend Use of 7-Dose Syringes for Pfizer Vaccine: Top Spokesman
March 10, 2021
- Medical Institutions Would Be Allowed to Provide 7 Doses per Vial of Pfizer’s COVID-19 Vaccine: Health Minister
March 10, 2021
- PMDA to Launch Working Group in April to Step Up Use of RWD
March 10, 2021
- Japan to Consider Ways to Speed Up Ivermectin Research for COVID-19
March 9, 2021
- Imfinzi, 2 Other Drugs under PMDA Safety Review
March 8, 2021
- Japan Speeds Up Vaccine Delivery for HCPs, Kono Says All 2nd Doses to Reach Municipalities in 1st Half of May
March 8, 2021
- MHLW Presents Views on “Pharma Industry Vision 2021” to LDP’s Project Team
March 8, 2021
- Japan Confirms 1st Case of Anaphylaxis from COVID-19 Vaccination
March 8, 2021
- Japan to Review Moderna Vaccine with Top Priority, May OK Possible: Minister
March 8, 2021
- Pfizer, Bayer to Pull Plug on “G1” Products with High Generic Erosions
March 5, 2021
- MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
- Vaccine Minister Says Govt to Stick to 3 Week Interval for Now
March 4, 2021
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…